Weather ALERT: We are actively monitoring the weather in our area to ensure patient and staff safety. Please see our NEWS Section and social media outlets for updates throughout the coming days. Arlington Office Patients: We apologize for any inconvenience. Currently our phones are down at our Arlington office. We hope for resolution soon. If you need to reach the Arlington office, please call our main number. Thank you for your patience.
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with both a lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and a synthetic peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/NY-ESO-1-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody-mediated immune responses against melanoma cells, which may result in melanoma cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
